Canaccord Genuity initiated coverage on Vicarious Surgical with a new price target
$RBOT
Industrial Specialties
Health Care
Canaccord Genuity initiated coverage of Vicarious Surgical with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $16.00 → $7.00 | Overweight → Neutral | Piper Sandler |
| 1/7/2022 | $16.00 | Outperform | Credit Suisse |
| 12/7/2021 | $15.00 | Outperform | Cowen & Co. |
| 11/5/2021 | $15.00 | Buy | Canaccord Genuity |
| 10/18/2021 | $15.00 | Buy | BTIG |
| 10/7/2021 | $16.00 | Overweight | Piper Sandler |
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical's manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel
Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers
Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h
Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the fourth quarter and fiscal year ended December 31, 2024 after the market closes on Monday, March 17, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 373279. A live and archived webcast of the event will be availabl
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2024. "Our team's strong execution throughout the year, continuing in the third quarter, has us on track to achieve our Version 1.0 System integration milestone within the next few weeks," said Adam Sachs, Co-Founder and Chief Executive Officer. "This sets the stage for us to complete our first clinical patient in less than a year, a criti
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
4 - Vicarious Surgical Inc. (0001812173) (Issuer)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)
SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)
Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h
Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a
Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari
Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously
Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00
Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00
8-K - Vicarious Surgical Inc. (0001812173) (Filer)
144 - Vicarious Surgical Inc. (0001812173) (Subject)
10-K - Vicarious Surgical Inc. (0001812173) (Filer)